Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Roseiflexus castenholzii is a heterotrophic, thermophilic, filamentous anoxygenetic phototroph (FAP) bacterium. This species is in one of two genera of FAPs that lack chlorosomes. R. castenholzii was first isolated from red-colored bacterial mats located Nakabusa hot springs in Japan. Because this organism is a phototroph, it utilizes photosynthesis to fix carbon dioxide and build biomolecules. R. castenholzii has three photosynthetic complexes: light-harvesting only, reaction center only, and light-harvesting with reaction center.
== Presence in cardiac lesions == The cardiac manifestations of rheumatic fever are in the form of focal inflammatory involvement of the interstitial tissue in all 3 layers of the heart, a pathological change named pancarditis. The pathognomonic feature of pancarditis in the case of rheumatic heart disease is the presence of Aschoff nodules or Aschoff bodies.
=== Biomimetic mineralization === Biomolecules can be incorporated during the MOF crystallization process. Biomolecules including proteins, DNA, and antibodies could be encapsulated within ZIF-8. Enzymes encapsulated in this way were stable and active even after being exposed to harsh conditions (e.g. aggressive solvents and high temperature). ZIF-8, MIL-88A, HKUST-1, and several luminescent MOFs containing lanthanide metals were used for the biomimetic mineralization process. In addition, individual living cells were encapsulated within MOF shells via single-cell nanoencapsulation (SCNE).
In 1876, the former GOCA Freemason and high-ranking member in the Provincial Mother Lodge member Aurelio Almeida y González went on a tour of the United States. Here, he obtained broad support from the Masonic bodies of North America. In July 1876, back in Cuba, the Mother Lodge started asking questions about the money that the Supreme Council had been asking the Lodges to pay, and insisted on a proper accounting – but their effort was suppressed. Later in July, Almeida y González sent a telegraph cable to the Mother Lodge. On July 28, 1876, days after Almeida y González's telegraph arrived in Cuba, the Mother Lodge dissolved itself. On August 1, 1876, representatives from thirteen Cuban lodges (9 chartered lodges and 4 under dispensation) met in Havana to form the Gran Logia de la Isla de Cuba (English: Grand Lodge of the Island of Cuba). Under the charter of the Grand Lodge of Island of Cuba, the Higher Degrees were overseen in Cuba by the Grand Orient of Spain and Práxedes Mateo Sagasta. Within a month, the Grand Lodge of Cuba possessed 17 lodges. The new "Cuban" Freemasonry was effectively a restructuring and reorganization of GOCA Freemasonry and its Lodges, but the Grand Lodge of Cuba was now considered "regular and correct," officially abandoning GOCA's ideology of direct political action. This allowed them to obtain recognition from the majority of Grand Lodges in North America. In mainland Spain, the Spanish Restoration was underway, and the Cuban government was starting to introduce new legislation and freedoms with the aim to end the Ten Years' War.
Testosterone, an androgen secreted by the testes, will cause changes in the cartilages and musculature of the larynx for males during puberty, and to a lesser extent to females assigned at birth and others such as intersex individuals as well as those who are androgen deficient if they are given masculinizing hormone therapy. In females, androgens are secreted principally by the adrenal cortex and the ovaries and can have irreversible masculinizing effects if present in high enough concentration. In males, they are essential to male sexuality. In muscles, they cause a hypertrophy of striated muscles with a reduction in the fat cells in skeletal muscles, and a reduction in the whole body fatty mass. Androgens are the most important hormones responsible for the passage of the boy-child voice to adult male voice, and the change is irreversible without reconstructive surgery such as feminization laryngoplasty. The thyroid prominence, which contains the vocal cords appears, the vocal folds lengthen and become rounded, and the epithelium thickens with the formation of three distinct layers in the lamina propria. These changes are also irreversible without surgery, albeit the thyroid/laryngeal prominence, also known as an Adam's apple can be potentially diminished via a tracheal shave or feminization laryngoplasty.
Sources: en.wikipedia.org
The end of the Cold War allowed many technologies that had been off limits to the public to be declassified. The most important of these is the Internet, which was created as ARPANET as a system to keep in touch after an impending nuclear war. The last restrictions on commercial enterprise online were lifted in 1995. The commercialization of the Internet and the growth of the mobile phone system increased globalization (as well as nationalism and populism in reaction). In the years since then, the Internet's population and usefulness have grown immensely. Only about 20 million people (less than 0.5 percent of the world's population at the time) were online in 1995, mostly in the United States and several other Western countries. By the mid-2010s, more than a third of the world's population was online. Further research continued into other Cold War technologies with the declassification of the Internet. While Ronald Reagan's Strategic Defense Initiative proved untenable in its original form, the system lives on in a redesigned state as the Aegis Ballistic Missile Defense System (BMDS). Countermeasures such as BMDS continue to be explored and improved upon post–Cold War, but are often criticized for being unable to effectively stop a full nuclear attack. Despite advances in their efficacy, anti-ballistic missiles are often viewed as an additional piece to modern day diplomacy where concepts such as mutual assured destruction and treaties such as that between Ronald Reagan and Mikhail Gorbachev following their Reykjavík Summit.
However, the conclusion was ambiguous as the overall content was above that expected of a male, and variations across the body may have been due to environmental factors. Similarly, green deposits were found in the hair, originally thought to be a copper-based pigment used for decoration, but it was later found to be the result of a reaction between the keratin in the hair and the acid of the peat bog.
== Before Tiselius == Early work with the basic principle of electrophoresis dates to the early 19th century. The electrokinetic phenomenon was observed for the first time in 1807 by Russian professors Peter Ivanovich Strakhov and Ferdinand Frederic Reuß at Moscow University, who noticed that the application of a constant electric field caused clay particles dispersed in water to migrate. Experiments by Johann Wilhelm Hittorf, Walther Nernst, and Friedrich Kohlrausch to measure the properties and behavior of small ions moving through aqueous solutions under the influence of an electric field led to general mathematical descriptions of the electrochemistry of aqueous solutions. Kohlrausch created equations for varying concentrations of charged particles moving through solution, including sharp moving boundaries of migrating particles. By the beginning of the 20th century, electrochemists had found that such moving boundaries of charged particles could be created with U-shaped glass tubes. Methods of optical detection of moving boundaries in liquids had been developed by August Toepler in the 1860s; Toepler measured the schlieren (shadows) or slight variations in optical properties in inhomogeneous solutions. This method combined with the theoretical and experimental methods for creating and analysing charged moving boundaries would form the basis of Tiselius' moving-boundary electrophoresis method.
== Chemical-physical characteristics == It is a dense red-violet liquid, but the color can vary based on the pH of the environment (reddish in an acidic environment, bluish in a basic environment). Chemically, enocyanin is a mixture of mono and dimethyl compounds of multiple anthocyanidins, it is soluble in hydroalcoholic solutions and insoluble in lipid solvents. The substance is listed together with other anthocyanins among food additives with the acronym "E163" (grape skin extract) and is marketed in the form of a dark red-purple powder to be dissolved in water or directly liquid. It is extracted from by-products of red winemaking (e.g. grape marc) and must be stored in a protected environment, preferably in the dark and away from heat sources. It fears humidity, oxidation and photodegradation, which transform it into insoluble brownish compounds typically found in poorly stored red wines.
=== Starvation === Starvation is a rare cause of ketoacidosis, usually instead causing physiologic ketosis without ketoacidosis. Ketoacidosis from starvation most commonly occurs in the setting of an additional metabolic stressor such as pregnancy, lactation, or acute illness.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.